Pluristem Receives Regulatory Korean Approval to Extend Phase II Study of PLX-PAD Cells for Treatment of IC
November 13, 2013 at 06:08 AM EST
Pluristem Therapeutics (NASDAQ: PSTI ) announced today that the South Korean Ministry of Food and Drug Safety (MFDS), formerly the Korea Food & Drug Administration (KFDA), has approved Pluristem's Investigational New Drug (IND) Application to conduct a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication